# XGene Pharmaceutical

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/xgene-pharmaceutical

- Industry: Pharmaceuticals
- Headquarters: Shanghai, China
- Website: www.xgenepharm.com/
- Total disclosed funding: $97M
- Latest round: Series D (Jul 28, 2026)
- Investors on record: 15

## About

Based in Shanghai, China and established in 2015, Xgene Pharmaceutical Inc., trading as XGene Pharmaceutical, is medicine research that focuses on providing molecular medicine for pain, communicable disease and tumor. In July 2026, XGene Pharmaceutical raised CNY 250 million in series D funding co-led by Efung Capital and GTJA Investment Group, with participation from Winfund Investment, Real Capital Global and other investors.

The company main business is the development and combination therapy of small molecule drugs for the treatment of pain, infectious diseases and tumors. The company has a self-developed product XG005 which is a non-opioid analgesic product.

The company's revenue is generated by providing XG005 which is a non-opioid analgesic product, and combination therapy of small molecule drugs for the treatment of pain, infectious diseases and tumors. 

The company will use the latest funding for the Phase III acute pain clinical trial of its first-launch product, XG005, in the United States, and to support the continued development and global expansion of the company's core product pipeline.

## Funding rounds

- Series D, Jul 28, 2026, $37M — GTJA Investment Group, Efung Capital, Winfund Investment, Real Capital Global
- Series C, Nov 5, 2021, $40M — Ping An Insurance Group, CITIC Securities, Neovision Capital, Yijing Investment, GSR United Capital, Tao Capital, Hengxu Capital
- Series B, May 4, 2019 — Taiwania Capital
- Series B, Oct 24, 2018, $20M — 5Y Capital, Ping An Insurance Group, TF Capital, Zhongtai Investment
- Series A, Oct 1, 2017 — 5Y Capital, TF Capital

## Investors

- 5Y Capital (https://capitalatlas.ai/funds/5y-capital) — Series A, Series B
- TF Capital — Series A, Series B
- Ping An Insurance Group — Series B, Series C
- Zhongtai Investment — Series B
- Taiwania Capital (https://capitalatlas.ai/funds/taiwania-capital) — Series B
- CITIC Securities — Series C
- Neovision Capital (https://capitalatlas.ai/funds/neovision-capital) — Series C
- Yijing Investment (https://capitalatlas.ai/funds/yijing-investment) — Series C
- GSR United Capital (https://capitalatlas.ai/funds/gsr-united-capital) — Series C
- Tao Capital (https://capitalatlas.ai/funds/tao-capital) — Series C
- Hengxu Capital (https://capitalatlas.ai/funds/hengxu-capital) — Series C
- GTJA Investment Group (https://capitalatlas.ai/funds/gtja-investment-group) — Series D
- Efung Capital (https://capitalatlas.ai/funds/efung-capital) — Series D
- Winfund Investment (https://capitalatlas.ai/funds/winfund-investment) — Series D
- Real Capital Global — Series D